SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
KS and KSHV: New Developments in Diagnosis, Therapy, and Pathogenesis
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
7 of
7
|
Session Overview
James A. Hoxie
University of Pennsylvania, Philadelphia, PA, USA
Validation of Quantification of Lesional KSHV DNA Content for Diagnosis of Kaposi Sarcoma in Africa (ABSTRACT
789)
Aggrey Semeere
Infectious Diseases Institute, Kampala, Uganda
Impact of Low-Dose Intra-Lesional Nivolumab for Kaposi Sarcoma on T-Cell Proliferation and Function (ABSTRACT
792)
Chia-Ching Wang
University of California San Francisco, San Francisco, CA, USA
Immunologic Responses to Pomalidomide and Liposomal Doxorubicin for Kaposi Sarcoma Treatment (ABSTRACT
791)
Matthew Witterholt
National Cancer Institute, Bethesda, MD, USA
Causes of Death Among Adults With HIV-Associated Kaposi Sarcoma in East Africa in the Treat All Era (ABSTRACT
794)
Helen Byakwaga
Infectious Disease Institute, Kampala, Uganda
Genome Evolution of Kaposi Sarcoma-Associated Herpesvirus (KSHV) in PLWH (ABSTRACT
796)
Dirk P. Dittmer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Discussion with Audience Q&A
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
7 of
7
|
